Intraoperative radiation therapy deserves to be made more readily available to patients by Keshtgar, M & Williams, NR
Editorial
Intraoperative radiation therapy deserves to be made more readily 
available to patients
Mohammed Keshtgar, Norman R. Williams
The Breast Unit, Royal Free Hospital, Royal Free London Foundation Trust, Hampstead, London NW3 2QG, UK
Correspondence to: Norman R. Williams, PhD, Principal Research Associate. The Breast Unit, Royal Free Hospital, Royal Free London Foundation 
Trust, Pond Street, Hampstead, London NW3 2QG, UK. Email: norman.williams@ucl.ac.uk.
Submitted Jan 18, 2016. Accepted for publication Feb 01, 2016.
doi: 10.21147/j.issn.1000-9604.2016.04.10
View this article at: http://dx.doi.org/10.21147/j.issn.1000-9604.2016.04.10
Whole breast external beam radiotherapy is an effective 
adjuvant treatment for early breast cancer, and was a key 
factor in the move from mastectomy to breast-conserving 
surgery for women with low-risk disease. The logical 
development from partial surgical removal of the breast is 
partial breast radiotherapy. Several methods of delivery have 
been investigated, but as yet none has been widely accepted.
The article by Vincent Vinh-Hung and colleagues 
describes very well their experience with the use of a single 
dose of low kilovoltage X-rays delivered intra-operatively 
from within the breast using Intrabeam® (the TARGIT 
technique) (1). Although the results are from a single site 
with a relatively small number of patients and short follow-
up (median 370 days), their data are consistent with the 
results from the short and intermediate term (median 2.4 y) 
follow-up data from the TARGIT A randomised controlled 
trial (2). In particular, it is noteworthy that the reported 
toxicities with Intrabeam® are less than the institution’s own 
retrospective control group that received external beam 
radiotherapy.
It has been shown that TARGIT can be applied to a large 
proportion of patients with early breast cancer, either as 
sole (TARGIT alone) or as a replacement for the tumour-
bed boost (TARGIT boost) (3), regardless of age (4). This 
is important, as evidence is growing for the long-term 
toxicities of whole-breast radiotherapy, as normal tissues are 
inevitably exposed to radiation. For example, conventional 
radiotherapy delivers a mean dose of 5.2 Gy to the heart (5). 
Even with modern radiotherapy techniques, the heart 
receives an appreciable dose of radiation. Mean heart dose 
for intensity modulated radiotherapy (IMRT) was 12.9±3.9 
vs. 4.5±2.4 Gy for 3D conformal radiation therapy (3DCRT). 
Heart volumes receiving >40 Gy were 2.6% (3DCRT) 
vs. 1.3% (IMRT); doses were >50 Gy with 3DCRT (6). 
Breath-holding techniques and prone positioning of the 
patient are effective and can reduce the volume of heart 
in the radiotherapy field, but there is limited data on late 
cardiac events (7). Even a single fraction of external beam 
radiotherapy can produce measurable changes to the DNA 
of circulating lymphocytes (8). Exposing women with 
small, focal, screen-detected lesions to these risks should be 
questioned more widely.
There are several other reasons why the use of 
Intrabeam® should be considered; for reviews, see (9-11). 
Ultimately, we agree with the author’s final sentence: “The 
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